Huapont Shengchem to Exhibit at CPhI Korea 2026, Expanding API Collaboration Opportunities in Asia-Pacific

From August 25 to 27, 2026, COEX Convention Center in Seoul, Korea, will host CPHI Korea 2026 – a key event of the CPhI global series and a vital platform connecting pharmaceutical suppliers, buyers, and decision-makers across the Asia-Pacific region. Chongqing Huapont Shengchem Pharmaceutical Co., Ltd. is pleased to announce its participation in this prestigious gathering at Booth J37, and cordially invites global partners to visit and explore collaboration opportunities.

CPhI Korea 2026 is expected to attract over 12,000 professional visitors and more than 420 exhibitors from over 80 countries and regions, marking a new record in scale and reach. The exhibition focuses on pharmaceutical, biopharmaceutical, and health innovation, offering three days of intensive business networking and knowledge exchange.

At this year’s event, Huapont Shengchem will highlight its differentiated API portfolio across more than 20 therapeutic areas, including retinoids, vitamin D3 derivatives, and oncology products, alongside its one‑stop CDMO capabilities spanning from intermediates to APIs and from gram‑scale to ton‑scale production. Founded in 1994 as a core subsidiary of Huapont Life Sciences (SZSE: 002004), the company operates two manufacturing sites and one R&D center in Chongqing, with products approved for registration in over 60 countries including China, the United States, the European Union, and Japan.

We sincerely welcome you to visit us at Booth J37 at COEX Convention Center in Seoul. 

Schedule a meeting, please contact:

Email: api@huapont.cn

Website: https://www.huapontshengchem.com/

You are welcome to visit our official website or send us an email. Our business team will arrange a dedicated meeting for you as soon as possible.